How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,983 results for

Ketoconazole

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Nystatin

-41 984105 Curr Med Res Opin. 1975;3(2):83-8 1095310 Br J Obstet Gynaecol. 1975 Nov;82(11):922-6 1191608 MMW Munch Med 1981 11. A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin , and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin , and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles (...) " Search for studies: Study Record Detail A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin , and Ketoconazole Tabs (...) . In adults, ketoconazole is used and sometimes oral nystatin . Both drugs are relatively expensive compared to GV solution and ketoconazole has significant side effects especially in association with some of the treatments for HIV related problems. In children, either GV solutions or nystatin are used, GV is a fraction of the cost of nystatin . GV at 1% solution discolours

2018 Trip Latest and Greatest

203. Sufentanil citrate (Dzuveo) - Pain

on the clinical studies conducted for Zalviso (SST 15 µg): the BA study IAP102, the two PK studies IAP101 and ARX-F01-01 and the PK drug interactions study (ketoconazole) IAP104. The results of the BA and PK studies submitted to support the marketing authorisation for SST 30 mcg showed that systemic exposure of sufentanil after Sufenta IV 30 mcg was greater than after single- dose SST 30 mcg. The mean bioavailability (F) approximately the same after administration of single- dose SST 30 mcg and 2 doses of SST

2018 European Medicines Agency - EPARs

204. Budesonide (Jorveza) - to treat adults with eosinophilic oesophagitis

is not a substrate for OATP1B3. Assessment report EMA/774645/2017 Page 23/83 Conversely in vitro interaction studies (Lu et al.: Drug Metab Dispos 2008 and Jönsson et al.: Drug Metab Dispos. 1995) have demonstrated strong inhibition of the metabolic degradation of budesonide by specific inhibitors of CYP3A4; i.e. ketoconazole. Contrary to CYP3A4 inhibitors, compounds or drugs such as carbamazepine and rifampicin, which are able to induce CYP3A4, might reduce the systemic exposure but probably also the local (...) 850.1500) by end of 2018, to which the applicant committed. 2.3.6. Discussion on non-clinical aspects The literature review on the safety pharmacology of budesonide is considered adequate. In vitro studies have demonstrated strong inhibition of the metabolic degradation of budesonide by specific inhibitors of CYP3A4; i.e. ketoconazole. In humans a clear influence of ketoconazole on the pharmacokinetics of budesonide was observed. The Applicant pointed out that a potential inhibition of the metabolic

2018 European Medicines Agency - EPARs

205. Drug-induced gynaecomastia

; some cancer drugs; ketoconazole; and isoniazid. When a patient complains of gynaecomastia, it is worthwhile reviewing with him the list of drugs he is taking or has recently taken, not forgetting products which are not classified as medicines. Their role should be considered among the range of potential causes. ©Prescrire 1 November 2018 Share Share Download the full review. | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously

2018 Prescrire

206. Dolutegravir sodium rilpivirine hydrochloride (Juluca) - HIV Infections

First-order rate of absorption KF Karl Fischer titration KTZ Ketoconazole LC-MS-MS Liquid chromatography tandem mass spectroscopy LDL Low-density lipoprotein LDPE Low density polyethylene LOCF Last observation carried forward LOD Loss on drying LPV/RTV Lopinavir/ritonavir LS Least square MAH Marketing authorisation holder MATE Multidrug and toxin extrusion transporter N(t)RTI Nucleotide HIV-1 reverse transcriptase inhibitor NA Not applicable NDA New Drug Application NF National formulary NGMN

2018 European Medicines Agency - EPARs

207. Sodium zirconium cyclosilicate (Lokelma) - Hyperkalemia

, lanthanum carbonate, docusate sodium, furosemide, glipizide, lisinopril, metformin HCl, quinapril HCl, spironolactone, valsartan, sevelamer carbonate, atorvastatin calcium, erythromycin ethylsuccinate, clopidogrel, ketoconazole, prednisone, warfarin sodium, allopurinol, amlodipine besylate, acetilsalicylic acid, cyclosporine, dabigatran etexilate, phenytoin. In vitro tests were performed according to GLP requirements using USP dissolution EMA/93250/2018 Page 18/103 methods as well as aqueous solutions (...) (OH)3, MgCO3, glipizide, ketoconazole, levothyroxine sodium, losartan potassium, valsartan. Based on the pH solubility profile and pH study data all changes were attributed to the ZS-induced change in the pH of the media and not to uptake/binding by ZS. The KEC of sodium zirconium cyclosilicate was unaffected by the presence of other drug substances with the possible exception of lithium carbonate capsules, USP 300 mg where a 10 - 12% decrease was noted. This minor decrease was attributed

2018 European Medicines Agency - EPARs

208. Antiplatelet medicines

. However, the risks should still be borne in mind and the patient should be closely monitored. Concomitant use of antiplatelet medicines with NSAIDs and/or SSRIs also increases the risk of bleeding. 5 Ticagrelor levels, and therefore the risk of bleeding, are increased where ‘strong’ CYP3A4 inhibitors are co-prescribed. Co-administration of ticagrelor with ritonavir, ketoconazole, clarithromycin, nefazodone, or atazanavir is contraindicated. 5 Decreased efficacy There is some evidence that the effect

2018 WeMeReC

209. Treatment algorithm for Cancer-associated Thrombosis (CAT)

agents Vinblastine ? ? ? Anti-mycotic agents Azithromycin ? ? ? Clarithromycin ? ? ? Erythromycin ? ? ? Itroconazole ? ? ? Ketoconazole ? ? ? Posaconazole — ? ? Voriconazole — ? ? Anthracyclines Doxorubicin ? ? ? Hormonal agents Tamoxifen ? ? ? Immune-modulating agents Cyclosporine ? ? ? Dexamethasone ? ? ? Tacrolimus ? ? ? Protease inhibitors Indinavir ? ? ? Nelfinavir ? ? ? Ritonavir ? ? ? Saquinavir ? ? ? Tyrosine kinase inhibitors Imatinib — ? ? Lapatinib ? ? ? Nilotinib ? ? ? Sunitinib

2018 Thrombosis Interest Group of Canada

210. Ticagrelor for preventing atherothrombotic events after myocardial infarction

with a strong CYP3A4 inhibitor (for example, ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir) is also contraindicated. The most commonly reported adverse effects include dyspnoea, epistaxis, gastrointestinal haemorrhage, subcutaneous or dermal bleeding, and bruising. For full details of adverse reactions and contraindications, see the summary of product characteristics. Recommended Recommended dose and dose and schedule schedule Ticagrelor 60 mg twice daily is the recommended dose when

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

211. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis

of antifungal susceptibility testing should take into account the acid pH of the vagina compared with the neutral pH at which testing is usually performed; the activity of azole antifungals is reduced in acidic environment and clinical resistance may occur despite the isolate being microbiologically susceptible. Treatment: • Oral azoles – continue to avoid in pregnancy, at risk of pregnancy and whilst breastfeeding • Ketoconazole is no longer recommended for the treatment of VVC • Non-azole therapies (...) does not support the use of low dose protracted regimens such as fluconazole 50mg od for 14- 28 days for recurrent VVC and suggests there is potential for development of antifungal resistance 98 • There is a low risk of idiosyncratic drug-induced hepatitis with oral azoles, although fluconazole is less frequently associated with hepatotoxicity than itraconazole (see later ‘Reactions to treatment’); • Oral ketoconazole is no longer recommended for the treatment of fungal infections due to the risk

2019 British Association for Sexual Health and HIV

212. Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings

suppress the hypothalamic-pi- tuitary-adrenal (HPA) axis. 9 10 Other medications, such as megestrol acetate, ketoconazole, and mifepristone, also impair adrenal function via direct and indirect mecha- nisms. Less common secondary causes of ACTH deficiency involving the pituitary and hypothalamus include tumors, radiation exposure, congenital anomalies, and specific gene defects (table 1 and box 1). Inherited forms of ACTH deficiency are usually associated with additional pituitary hormone deficiencies (...) polyendocrinopathy type 2. ? Bilateral hemorrhage/infarction – Trauma. – Waterhouse-Friderichsen syndrome. – Anticoagulation. ? Drug effect: mifepristone, aminoglutethimide, mitotane, ketoconazole, etomidate, metyrapone, rifampin, phenytoin, barbiturates, tyrosine kinase inhibitors (eg, sunitinib) ? Infection – Viral: HIV, cytomegalovirus. – Fungal: coccidioidomycosis, histoplasmosis, blastomycosis, cryptococcosis. – Mycobacterial: tuberculosis. – Amebic. ? Infiltrative – Hemochromatosis, histiocytosis

2019 Pediatric Endocrine Society

219. Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic hepatitis C genotypes 1 and 4

concentration. This can increase the risk of ALT elevations. GRZ/EBR is contraindicated with OATP1B1/3 inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations, including: rifampicin atazanavir, darunavir, lopinavir, saquinavir and tipranavir ciclosporin. Precautions Caution should be used when co-administering GRZ/EBR with: strong cytochrome P450 3A4 inhibitors (eg, ketoconazole and ritonavir), which may lead to increased concentrations of elbasvir and grazoprevir

2018 National Prescribing Service Limited (Australia)

220. Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo

Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01203189 Recruitment Status : Completed First Posted : September 16, 2010 Results First Posted : November 6, 2017 Last Update Posted : November 6, 2017 Sponsor: St. Louis University

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>